Browsing: cardiovascular

Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not…

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was…

The first-ever European Society of Cardiology Guidelines on the management of cardiovascular disease and chronic kidney disease have been developed…

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Obesity, given its strong association with cardiovascular diseases (CVDs),…